Abstract
Purpose
To evaluate the incremental effect of perfusion imaging on biopsy target identification
at endorectal multiparametric prostate magnetic resonance imaging (MRI).
Materials and methods
We retrospectively 52 patients who underwent endorectal multiparametric prostate MRI
for suspected or untreated prostate cancer. Two readers independently identified biopsy
targets without and with perfusion images.
Results
Reader 1 identified 36 targets without and 39 targets with perfusion imaging (P>.05). The corresponding numbers for reader 2 were 38 and 38, respectively (P=.5).
Conclusion
Perfusion imaging does not significantly increase the number of biopsy targets identified
at endorectal multiparametric prostate MRI.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- MR imaging of the prostate.Radiol Clin North Am. 2014; 52: 811-837
- Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.J Natl Cancer Inst. 2007; 99: 1395-1400
- Early detection of prostate cancer: AUA Guideline.J Urol. 2013; 190: 419-426
- Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.J Magn Reson Imaging. 2013; 37: 1035-1054
- Direct MRI-guided biopsy of the prostate: use of post-biopsy needle track imaging to confirm targeting.Abdom Imaging. 2015; 40: 2517-2522
- Prostate cancer: multiparametric MR imaging for detection, localization, and staging.Radiology. 2011; 261: 46-66
- Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.Radiology. 2011; 259: 775-784
- PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.Eur Urol. 2016; 69: 16-40
- Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.AJR Am J Roentgenol. 2012; 198: 1277-1288
- Immediate hypersensitivity reaction to gadolinium-based MR contrast media.Radiology. 2012; 264: 414-422
- Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging?.Diagn Interv Radiol. 2011; 17: 243-248
- Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience.J Magn Reson Imaging. 2014; 40: 314-323
- Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.Eur Urol. 2014; 66: 22-29
- Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.Eur Urol. 2013; 64: 713-719
- Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy.Urol Oncol. 2014; 32: 903-911
- The measurement of observer agreement for categorical data.Biometrics. 1977; 33: 159-174
- Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer.Gastroenterology. 2012; 143: 844-857
- U.S. health care: a conundrum and a challenge.World Neurosurg. 2013; 80: 691-698
- Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.Eur Urol. 2013; 63: 125-140
Article info
Publication history
Published online: January 27, 2016
Accepted:
January 23,
2016
Received:
November 13,
2015
Footnotes
☆DP supported by National Institute of Biomedical Imaging and Bioengineering grant 1R25EB016671.
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
